Wanbury reports 88% drop in Q3 FY25 PAT
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated